Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen launches new Explorer trial programme for Xarelto

Janssen launches new Explorer trial programme for Xarelto

14th March 2013

Janssen has announced the launch of Explorer, a comprehensive global research programme centring on the oral anticoagulant Xarelto, which it developed alongside Bayer HealthCare.

The programme will involve five trials – Commander-HF, Compass, Pioneer AF-PCI, X-VeRT and Venture-AF – assessing the drug for investigational use among patients with chronic heart failure, coronary artery disease or peripheral artery disease.

Once these trials are completed, Xarelto will become the most studied oral Factor Xa inhibitor in the world, with more than 100,000 patients having participated in its clinical development programme.

The drug has the broadest indication profile of any therapy of its kind and has been approved for six distinct uses thus far.

Troy Sarich, vice-president and compound development team leader at Janssen's research and development division, said: "The Explorer program seeks to build upon the broad set of approved indications and further assess potential benefits of Xarelto in additional patient populations who may benefit from oral anticoagulation treatment."

Last week, the company announced that it has submitted a marketing authorisation application to the European Medicines Agency for a potentially promising new combination therapy for type 2 diabetes.ADNFCR-8000103-ID-801556243-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.